BioAdvance - Unicorn Nest



This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Headquarters Location

United States, Philadelphia


BioAdvance is the renowned VC, which was created in 2003. The the headquarters of this VC is in Philadelphia. This investor is located in North America, United States.

Among the most popular investment industries for the fund are Health Diagnostics, Pharmaceutical. However, the fund’s focus is not limited to this, since there are 9 more areas of investment. Advaxis, Wellsheet, Bainbridge Health are amongst the various portfolio companies of this fund. The fund has specific requirements for the number of founders in a start-up. When a start-up has 4 or 5+ founders, the probability of closing the deal is low. The country of its foundation and the country of the most frequent investments for the fund coincides - United States. Moreover, a start-up needs to be 2-3 years old to get investment from this fund.

The usual method for the fund is to invest in rounds with 1-2 other investors. Along with BioAdvance, start-ups are often financed by Ben Franklin Technology Partners of Southeastern Pennsylvania, Dorm Room Fund, Robin Hood Ventures as well as 14 other investors. Other VCs who often invest in the same rounds are Ben Franklin Technology Partners of Southeastern Pennsylvania, Safeguard Scientifics, iSeed Ventures, the total number of co-investors is 25. In subsequent rounds, the fund is usually joined by Ben Franklin Technology Partners of Southeastern Pennsylvania, Safeguard Scientifics, Robin Hood Ventures, as well as 22 other investors.

Besides the listed founders, we have found 5 key employees of this fund in our database.

In terms of the fund's performance, this VC has 11 percentage points less exits when compared to other organizations. The highest number of exits from this fund were in 2010. Deals in the range of 5 - 10 millions dollars are most common for this fund. The fund usually participates in 7-12 investment rounds per year. This fund was the most active in 2010. Additionally, in 2019 the fund was active. In comparison with other funds, BioAdvance makes 21 percentage points less than the average number of lead investments.

Year Founded


Fund Activity


Mail Rule [rules by which you can get an email of an interesting for you fund employee, knowing only the name and surname of this employee]

Domain name:; User name format in descending order of probability: first_initial last, first last, last first_initial, first, first last_initial

Group Appearance [how often fund is operating separately from groups with shared interest]

92.3% of cases

Investments per Year [average amount of rounds in which fund participates each year]


Follow-on Index [how often fund is ready to support its portfolio startup at next rounds]

46.4% of cases

Average Multiplicator [the average ratio of the last valuation of portfolio startups to their total amount of financing raised]


Average Portfolio Company
Exit Age [the average age of portfolio startups at which they go public or become acquired]

3.7 years

Success / Strategy Similarity
Index [the matching between fund's investment strategy and its proved successes in the form of portfolio startups high valuations]

0.11 out of 1

If you have found a spelling error or the data isn't actual, please, notify us by selecting that text and pressing Ctrl+Enter.

Fund reviews
  • No reviews are submitted yet.
Crunchbase icon

Content report

The following text will be sent to our editors: